The 24 most recent market catalysts affecting $NTRA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Natera shares are trading higher. The company announced that Japan's pharma and medical devices agency has approved its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.
This approval is a significant positive catalyst for Natera, opening up a new and substantial market for its Signatera test in muscle-invasive bladder cancer. The 'companion diagno…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
UBS Maintains Buy on Natera, Raises Price Target to $435
UBS analyst Doug Schenkel has maintained a 'Buy' rating on Natera and raised the price target from $290 to $435. This substantial increase in the price target, by over 50%, indicat…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385
Rothschild & Co's initiation of coverage on Natera with a 'Buy' rating and a $385 price target is a positive development for the company. Analyst coverage, especially with a strong…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera's 8-K filing details the publication of new data in 'Blood Neoplasia' demonstrating Signatera's superior ability to predict lymphoma outcomes and treatment response compared…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Natera, Raises Price Target to $365
This filing discloses that Citigroup, through its analyst Brendan Digan, has maintained a 'Buy' rating on Natera and raised its price target from $315 to $365. This is significant …
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5
Piper Sandler analyst David Westenberg has maintained an 'Overweight' rating on Natera (NTRA) and substantially raised the price target from $249 to $363.5. This significant increa…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Stephens & Co. Maintains Overweight on Natera, Raises Price Target to $350
Stephens & Co. analyst Mason Carrico has maintained an 'Overweight' rating on Natera and raised the price target from $305 to $350. This indicates a strong belief in the company's …
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on Natera, Raises Price Target to $360
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Natera and significantly raised the price target from $290 to $360. This action indicates a strong positive outlook from…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
TD Cowen Maintains Buy on Natera, Raises Price Target to $340
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $325 to $340. This action signals a strengthened positive outlook from a pr…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Natera, Raises Price Target to $315
Citigroup analyst Brendan Digan maintained a 'Buy' rating on Natera and raised the price target from $300 to $315. This action signals a continued bullish outlook from a major inve…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Maintains Outperform on Natera, Raises Price Target to $350
RBC Capital's analyst Dan Leonard maintained an Outperform rating on Natera and significantly raised the price target from $275 to $350. This action signals strong conviction from …
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
The filing highlights a strong day for several individual stocks, primarily driven by robust earnings reports and optimistic forward guidance. Natera, Doximity, PubMatic, and Airbn…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Natera, Raises Price Target to $360
JP Morgan analyst Casey Woodring maintained an 'Overweight' rating on Natera and raised the price target from $315 to $360. This action signals a positive outlook from a major inve…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Equal-Weight on Natera, Raises Price Target to $284
Wells Fargo analyst Evan Stampler maintained an 'Equal-Weight' rating on Natera but raised the price target from $220 to $284. This indicates that while the analyst believes the st…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $360
Evercore ISI Group analyst Daniel Markowitz maintained an Outperform rating on Natera (NTRA) and raised the price target from $300 to $360. This upgrade signals increased confidenc…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 92
Natera shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, BTIG raised its price target on the stock from $290 to $320.
This headline is a major positive catalyst for Natera (NTRA). The combination of beating Q2 expectations and significantly raising long-term sales guidance (FY26) signals robust bu…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Natera, Raises Price Target to $320
BTIG analyst Mark Massaro has maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $290 to $320. This action signals continued confidence from the analyst in…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Natera shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a major positive corporate catalyst for Natera. The combination of exceeding current quarter expectations and significantly increasing long-term sales guid…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Natera Raises FY2026 Sales Guidance from $2.740B-$2.820B to $2.850B-$2.910B vs $2.797B Est
Natera (NTRA) has updated its financial outlook for fiscal year 2026, raising its sales guidance from a range of $2.740 billion-$2.820 billion to $2.850 billion-$2.910 billion. Thi…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 95
Natera Q2 EPS $(0.47) Beats $(0.51) Estimate, Sales $752.750M Beat $660.687M Estimate
Natera's Q2 earnings report shows a significant beat on both EPS and sales estimates. The company reported losses of $(0.47) per share, beating the $(0.51) estimate, and sales of $…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Natera Submits Application To Japan’s Pharmaceuticals And Medical Devices Agency For Approval Of The Signatera Test In Muscle-Invasive Bladder Cancer As A Companion Diagnostic
Natera has filed an application with Japan's PMDA for its Signatera test in muscle-invasive bladder cancer, building on its prior approval in colorectal cancer. This move signifies…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 65
Natera Publishes Results From Prospective, Multicenter Study In Merkel Cell Carcinoma In The JAMA Dermatology Journal; Signatera Test Was A Significantly Stronger Predictor Of Recurrence Than AMERK
Natera published results from a prospective, multicenter study in JAMA Dermatology, highlighting the superior performance of its Signatera test over the AMERK test in predicting Me…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Natera Highlights Finalized MolDx LCD Expanding Prospera Testing Coverage Across Kidney, Heart, And Lung Transplant Surveillance Settings
The finalized MolDx LCD expanding Prospera testing coverage is a major positive catalyst for Natera. This regulatory approval significantly broadens the addressable market for thei…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $330
Canaccord Genuity analyst Kyle Mikson maintained a 'Buy' rating on Natera and raised the price target from $285 to $330. This action signals increased confidence from the analyst i…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.